Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Pharmacokinetics of Evacetrapib in Healthy Subjects

Trial Profile

Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Pharmacokinetics of Evacetrapib in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Evacetrapib (Primary) ; Omeprazole (Primary)
  • Indications Cardiovascular disorders; Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 10 Jun 2016 Primary endpoint has not been met. (Pharmacokinetics (PK): Time of Maximum Observed Concentration (tmax) of Evacetrapib), as per results published in the Pharmacotherapy.
    • 10 Jun 2016 Results (n = 34) published in the Pharmacotherapy.
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top